DKFZ 5 records found  Search took 0.01 seconds. 
[DKFZ-2022-03017] Journal Article
; ; ; et al
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. [...]
[DKFZ-2022-01699] Journal Article
; ; ; et al
Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma
European urology 81(4), 331 - 336 () [10.1016/j.eururo.2022.01.026]  GO
Recent molecular characterization of primary urothelial carcinoma (UC) may guidefuture clinical decision-making. For metastatic UC (mUC), a comprehensive molecularcharacterization is still lacking. [...]
[DKFZ-2022-01698] Journal Article
; ; ; et al
In-depth assessment of metastatic prostate cancer with high tumour mutational burden
Background: A comprehensive assessment of biopsies from metastatic prostate cancer (mPCa) patients (pts) may identify a molecular subset of pts susceptible for immune checkpoint (IC) blockade (ICB).Methods: 148 biopsies and germline DNA from 145 mPCa pts were whole genome sequenced (WGS) at an average of 114x and 38x. Tumour mutational (mut) burden (TMB) was defined as number of somatic single nucleotide variants and InDels per Mb of the genome, known mut signatures (Alexandrov, Nature 2013) extracted by non-negative least squares regression as well as recurrent mutations reported in mismatch repair (MMR) pts (Kim, Cell 2013). [...]
[DKFZ-2022-01695] Journal Article
; ; ; et al
68 Ga-PSMA–Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate Cancer
For individual treatment decisions in patients with metastatic prostate cancer (mPC), molecular diagnostics are increasingly used. Bone metastases are frequently the only source for obtaining metastatic tumor tissue. [...]
DBCoverage [DKFZ-2022-01683] Journal Article
; ; ; et al
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
Metastatic castration-resistant prostate cancer (mCRPC) has a highly complex genomiclandscape. With the recent development of novel treatments, accurate stratification strategies are needed. [...]

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.